QPHARMA
ActiveSummary
QPHARMA has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2,500 and a net result of €53,114. Equity is shrinking by ~48% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2026. Its solvency ranks better than 10% of 38,911 sector peers (NACE 70, fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
06-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
02-04
State Gazette act
Registered officeRegistered-office move2 facts ▸
State Gazette act
Registered office
Registered-office move2 facts ▸
- General meeting, assemblée générale extraordinaire
- Registered-office move, Rue Xavier de Bue n° 27 bte 9 à 1180 Uccle
2025
20-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 20 days late
2024
31-12
Financial
Weakest financial yearnet €46,845 ▼20.3%
Net result drops to €46,845, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity triplescurrent ratio 4.50
Current ratio from 1.41 to 4.50; short-term debt falls from €59,104 to €22,059.
31-12
Financial
Equity above €100,000Eq €108,139 ▲76.4%
2 profitable years in a row build equity to €108,139.
02-10
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 63 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 3 acts read
About the unread acts
Of the 3 Belgian State Gazette acts we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.